



Scientific Programme

Chairs: Nicole Concin, Xavier Matias-Guiu Guia, Anna Fagotti, Iain McNeish
17 & 18 November 2025
Vienna, Austria

Day 1: November 17, 2025			
08:00 Registration at the venue and welcome coffee			
8:20	Introduction, Welcome	Chairs: N Concin, X Matias-Guiu, A Fagotti, I McNeish	10`
OVARIAN CARCINOMA Chairs of the OC day: A Fagotti, I McNeish			
	Molecular Markers in High Grade Ovarian Cancer		
8:30	Precursor lesions of HGSOc: genomic features and possible therapeutic implications	Iain McNeish	20`
	Discussion		10`
9:00	Secondary prevention in OC: is it possible?	Anna Fagotti	20`
	Discussion		10`
9:30	Artificial intelligence in ovarian cancer histopathology	Konstantinos Zormpas-Petridis	20`
	Discussion		10`
10:00	Liquid biopsy in OC: limits and prospective	Iain McNeish	20`
	Discussion		10`
Coffee break 30 min (10:00 – 10:30)			
10:30	HRD test: pitfalls and new possible approach	Alexandra Leary	20`
	Discussion		10`
11:00	HRD + carriers who do not respond to platinum and/or PARP. Who are they and which possible explanations	TBA	20`
	Discussion		10`
11:30	Targeting folate receptor alpha in OC: future perspectives, other than the pl-resistant setting.	TBC	20`
	Discussion		10`
12:00	Her-2 amplification in OC: which expectations for therapy?	Christian Marth	20`
	Discussion		10`
12:30	Tumour profiling analysis of mucinous OC and possible therapeutic implications	Xavier Matias-Guiu Guia	20`
	Discussion		10`
13:00	Heterogeneity and immunobiology of OC and impact on IO resistance in OC	Jonathan Ledermann	20`

Course on Molecular Pathology and Targeted Therapy in Endometrial and Ovarian Cancer

November 17-18, 2025
VIENNA, AUSTRIA



	Discussion		10'
Lunch break 60min (13:30-14:30)			
	Non epithelial ovarian tumours		
14:30	Molecular/genetic pathways and treatment of low-grade ovarian tumours	Christoph Grimm	20'
	Discussion		10'
15:00	Integration of molecular pathology to define patients for fertility sparing management in endometrial and ovarian tumours: too early?	Philippe Morice	20'
	Discussion		10'
15:30	Basket trials in rare OC: are they feasible?	TBC	20'
	Discussion		10'
Coffe break 30 min (15:30-16:00)			
	Case studies		
16:00	Case 1		5'
	Discussion		15'
16:20	Case 2		5'
	Discussion		15'
16:40	Case 3		5'
	Discussion		15'
18:00	Wrap up Day 1	Chairs of the day: A Fagotti, I McNeish	5'
Welcome dinner (20:00) Meeting point: Hotel lobby			
Day 2: November 18, 2025			
08:20	Welcome Day 2	Chairs: N Concin, X Matias-Guiu, A Fagotti, I McNeish	10'
ENDOMETRIAL CARCINOMA Chairs of the EC day: N Concin & X Matias-Guiu Guia			
	Tumor Biology and Testing in Endometrial Carcinoma		
8:30	The game-changer: Molecular classification of Endometrial cancers (testing, IHC versus NG, relevance etc)	Xavier Matias-Guiu Guia	20'
	Discussion		10'
9:00	Biomarkers beyond Molecular classification (testing and relevance, eg TMB, DNA repair genes, ER/PR, HER2, Trop2 etc) and timing of testing (curettage material etc)	Sigurd Lax	20'
	Discussion		10'
9:30	LVS1: no/focal/substantial How to determine and to cluster? -the clinical experience - the pathological point of view	Francesco Fanfani Alicia Leon Castilio	20'

Course on Molecular Pathology and Targeted Therapy in Endometrial and Ovarian Cancer

November 17-18, 2025
VIENNA, AUSTRIA



	Discussion		10`
Coffee break 30min (10-10:30)			
10:30	"Synchronous" tumours: are they synchronous?	Xavier Matias-Guiu Guia	20`
	Discussion		10`
11:00	Integrating it all: AI and machine learning in endometrial carcinoma	Alicia Leon Castillo	20`
	Discussion		10`
11:30	The hereditary: Lynch syndrome (testing, tailored surveillance, prophylactic surgery etc)	Stephan Polterauer	20`
	Discussion		10`
Lunch break 60min (12-13:00)			
	The path to Clinics		
13:00	Risk group stratification (including ESGO app demonstration)	Remi Nout (e.g. Richard Schwammeis for app)	20`
	Discussion		10`
13:30	MMRd, the most clear? (consequences in adjuvant and advanced/recurrent setting, MLH1 methylation, non responders etc)	Jonathan Ledermann	20`
	Discussion		10`
14:00	None MMRd: the best, POLEmut	Nicole Concin, Remi Nout	20`
	Discussion		10`
14:30	None MMRd: the worst, p53 abnormal	Nicole Concin	20`
	Discussion		10`
Coffee break 30 min (15:00-15:30)			
15:30	None MMRd: the biggest and least attractive as non-specific? NSMP	TBC	0:30
	Discussion		0:10
16:00	Biomarker-driven beyond molecular subgroups (Her2, Trop 2 etc...)	Christian Marth	0:20
	Discussion		0:10
16:30	The challenges in molecular/biomarker driven treatment approaches (biomarker cut offs, sequence of approaches, same biomarker different drugs, timing treatment vs maintenance, etc)	Alexandra Leary	20`
	Discussion		10`
Coffee break 30min (17:00-17:30)			
	Case studies		
17:30	Case 1		5`
	discussion		15`
17:50	Case 2		5`
	Discussion		15`

*Course on Molecular Pathology and
Targeted Therapy in Endometrial and
Ovarian Cancer*

November 17-18, 2025
VIENNA, AUSTRIA



18:10	Case 3		5`
	Discussion		15`
18:30	Wrap up Day 1	Charis of the day: N Concin, X Matias-Guiu Guia	5`
18:35	Closing, evaluations	Chairs: N Concin, X Matias Guiu, OC Chairs	5`